Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
|Articles|September 22, 2015
Shaji Kumar on Later Lines of Treatment for Myeloma
Author(s)Shaji Kumar
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Related to this article
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.
Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.
My multiple myeloma nurse case manager sat in on every appointment, helped me appeal an insurance denial and made sure I never felt like just a number.
Advertisement
Advertisement